Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00584870 · ClinicalTrials.gov registry record · Phase 2

RN624 In Adult Patients With Chronic Low Back Pain

A Phase 2 study, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
220
Enrollment target

NCT00584870 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 220 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00584870, a Phase 2 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
220 participants
Enrollment target

Study Summary

The primary objective of this study is to evaluate the analgesic efficacy of RN624 compared with placebo and compared with naproxen in the treatment of adult patients with chronic low back pain.

Interventions

  • DRUG Placebo
  • DRUG Naproxen
  • DRUG PF-04383119 (RN624)

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2007-07-05
Est. Completion 2008-09-02
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00584870

The ClinicalTrials.gov registry entry for NCT00584870 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT00584870 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00584870 about?

NCT00584870 is a clinical study titled "RN624 In Adult Patients With Chronic Low Back Pain". The primary objective of this study is to evaluate the analgesic efficacy of RN624 compared with placebo and compared with naproxen in the treatment of adult patients with chronic low back pain.

What is the current status of trial NCT00584870?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2007-07-05. Estimated completion is 2008-09-02.

What interventions are being tested in trial NCT00584870?

The interventions under investigation include: Placebo (DRUG), Naproxen (DRUG), PF-04383119 (RN624) (DRUG).

Who is sponsoring clinical trial NCT00584870?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.